Brainsway (BWAY) has released an update.
BrainsWay has reported a robust start to 2024 with a 37% increase in year-over-year revenue for Q1 and positive net income and Adjusted EBITDA for the second and third consecutive quarters, respectively. The company is reiterating its full-year revenue guidance of $37 million to $40 million, indicating a 16% to 26% growth over the previous year. This performance underscores BrainsWay’s growth trajectory and continued profitability in the neurostimulation treatment market for brain disorders.
For further insights into BWAY stock, check out TipRanks’ Stock Analysis page.
